Two products, one starting material, and a persistent procurement mistake: treating intravenous immunoglobulin (IVIG) and human albumin as if they were two strengths of the same thing. They are not. A buyer who merges the two lines, or who accepts a quotation that swaps one for the other, has bought a product that does not answer the specification on the tender.
This comparison is written for licensed importers, distributors and tender authorities — the people who have to put the right product on the right line, with the right approval number, and hold the paperwork to prove it. It describes what each product is and how they differ, and ends with a decision guide for the procurement side.
The one-sentence difference
Human albumin is a single, highly purified plasma protein — one molecule, fractionated to a defined concentration. IVIG is a pooled preparation of the immunoglobulin fraction of plasma — a broad mixture of antibodies from thousands of donors, standardised to a specified protein content. Albumin is one protein; IVIG is a library of many.
Side-by-side comparison
| Dimension | IVIG | Human albumin |
|---|---|---|
| What it is | Pooled human immunoglobulin (a mixture of antibodies) | A single purified plasma protein |
| Source | Immunoglobulin fraction of pooled human plasma | Albumin fraction of pooled human plasma |
| Primary use | Immunoglobulin-related indications | Volume replacement and albumin-related indications |
| Concentration | 5% solution for infusion | 20% solution for infusion |
| Presentations | 2.5 g / 50 ml · 5 g / 100 ml | 5 g / 25 ml · 10 g / 50 ml |
| Storage | 2–8 °C, do not freeze | 2–8 °C, protected from light |
| Shelf life | 36 months | 36 months |
| Approval number | NMPA S19993012 | NMPA S10940011 · S10940012 |
| Manufacturer | China Resources Boya | China Resources Boya |
The approval numbers make the point in a single line: IVIG and human albumin carry different 国药准字 numbers because they are different registered products. A quotation that presents one number against the other product's line is a mismatch, not a substitution.
Why the difference matters at procurement
The distinction is not academic, and it shows up in three places the buying side has to get right.
Separate tender lines
IVIG and human albumin are specified for different indications, so they appear as separate lines in a tender and in the national essential-medicine and reimbursement frameworks of most markets. They are not interchangeable within a line, and they are not fungible units of "plasma product".
Separate registration dossiers
Each product holds its own registration certificate and its own batch release pathway. The dossier that registers IVIG does not register human albumin, and the import licence in the destination market names the specific product. Mixing the two at the dossier stage delays the whole file.
Same logistics, different paperwork
Both move at 2–8 °C and must not be frozen, so a single validated cold chain can serve both. But the batch release certificate, the certificate of analysis and the approval reference are product-specific. One cold chain, two document sets.
How to decide which one you need
The decision belongs to the specification, not to the buyer's preference. The question that resolves it is the indication named in the tender or the purchase request.
- If the requirement names immunoglobulin or antibody-related therapy, the line is IVIG.
- If the requirement names volume replacement or albumin-related therapy, the line is human albumin.
- If the requirement is ambiguous, stop and ask for the indication before quoting — the two products are not alternatives, and guessing is how a wrong order is placed.
Where the two genuinely do overlap is on the supplier side: both products come from the same manufacturer under the same export mandate, so a single channel can cover both lines without splitting the file.
Frequently asked questions
Are IVIG and human albumin the same thing?
No. Both are proteins fractionated from human plasma, but IVIG is a pooled immunoglobulin preparation, while human albumin is a single, highly purified protein. They are used for different clinical purposes and are not interchangeable.
Which one should a hospital tender specify?
It depends on the therapeutic indication in the tender, not on price. IVIG is specified for immunoglobulin-related indications; human albumin is specified for volume replacement and albumin-related indications. The two are separate tender lines and should not be merged.
Do IVIG and human albumin need the same cold chain?
Yes, both are shipped and stored at 2–8 °C and must not be frozen. The cold-chain validation and temperature-logger evidence required for one applies to the other.
Are the presentations the same?
No. IVIG is supplied as a 5% solution in 2.5 g / 50 ml and 5 g / 100 ml vials. Human albumin is supplied as a 20% solution in 5 g / 25 ml and 10 g / 50 ml vials. Strengths and vial sizes differ.
Can one supplier provide both?
Yes. Both products are supplied by China Resources Boya under wanyoda's export mandate, so a single manufacturer and a single export channel can cover both tender lines.
Where to go next
- Human Immunoglobulin for Intravenous Injection (IVIG) — full specification and approval reference for the IVIG line.
- Human Albumin 20% — full specification and approval reference for the albumin line.
- Documents a Chinese plasma supplier must provide — the document set that proves both products are lawful and in-spec.
- Product index — the full plasma-derived portfolio, by manufacturer.